Sign up to save your podcasts
Or
Share FDA approves second Alzheimer’s treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA approves second Alzheimer’s treatment
On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By POLITICO
4.7
453453 ratings
On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like POLITICO's Pulse Check
View all
POLITICO's Off Message
610 Listeners
The Conversation with Dasha Burns
1,524 Listeners
The Playbook Podcast
706 Listeners
The Daily
112,064 Listeners
Power Play
964 Listeners
Women Rule
307 Listeners
Up First from NPR
56,548 Listeners
Brussels Playbook Podcast
101 Listeners
What the Health? From KFF Health News
495 Listeners
POLITICO Money
207 Listeners
FT News Briefing
650 Listeners
Fiction - Comedy Fiction
6,445 Listeners
POLITICO Energy
138 Listeners
POLITICO Tech
386 Listeners
Westminster Insider
41 Listeners
POLITICO Berlin Playbook
11 Listeners
The Headlines
745 Listeners